Omeros Shares Are Trading Higher After the Company Announced That Narsoplimab Met Its Primary Trial Endpoint and Will Resubmit Its Narsoplimab Biologics License Application to the FDA.
Omeros Shares Are Trading Higher After the Company Announced That Narsoplimab Met Its Primary Trial Endpoint and Will Resubmit Its Narsoplimab Biologics License Application to the FDA.
奧麥羅製藥的股票在公司宣佈Narsoplimab達到了其主要試驗終點，並將重新向FDA提交Narsoplimab生物製品許可申請後上漲。
Omeros Shares Are Trading Higher After the Company Announced That Narsoplimab Met Its Primary Trial Endpoint and Will Resubmit Its Narsoplimab Biologics License Application to the FDA.
奧麥羅製藥的股票在公司宣佈Narsoplimab達到了其主要試驗終點，並將重新向FDA提交Narsoplimab生物製品許可申請後上漲。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間